Market Pulse

Latest company updates, ordered by publication date.

Chicago Automobile Trade Association

Chicago Auto Show's Charity Gala Signals Resilience Amidst EV Transition

Event summary

  • The Chicago Auto Show's 'First Look for Charity' gala will be held February 6, 2026, at McCormick Place.
  • The gala raises over $2 million annually for 18 local Chicago-area charities, totaling over $65 million since its inception.
  • Attendees will have a chance to win a 2026 Chevrolet Equinox and a 2026 Toyota Land Cruiser Hybrid.
  • Tickets are priced at $325, with $283.84 being tax-deductible.

The big picture

The Chicago Auto Show's 'First Look for Charity' gala represents a crucial revenue stream and community engagement strategy for the automotive industry, particularly as the sector navigates the shift towards electric vehicles and faces evolving consumer preferences. The gala's consistent fundraising success demonstrates the enduring appeal of experiential marketing and charitable partnerships, even amidst broader economic uncertainty. The event's scale—raising millions annually and involving numerous local businesses—underscores its significance to the Chicago economy.

What we're watching

Consumer Sentiment
The continued success of the gala, and the auto show itself, will be a barometer of consumer confidence and willingness to spend on discretionary items, especially large-ticket purchases like vehicles.
EV Adoption
The selection of a hybrid vehicle (Toyota Land Cruiser) as a prize suggests a cautious approach to fully electric vehicles, reflecting broader consumer hesitancy and the auto industry’s ongoing transition.
Sponsorship Dynamics
Men's Wearhouse's continued sponsorship and on-site rental services indicate a strategic alignment with the auto show’s demographic, but whether this partnership can be leveraged for broader retail growth remains to be seen.
The Chemours Company

Chemours to Pocket $360 Million from Taiwan Land Sale

Event summary

  • Chemours has agreed to sell the remaining land at its former titanium dioxide manufacturing site in Kuan Yin, Taiwan.
  • The sale is expected to generate approximately $360 million in gross cash proceeds.
  • The transaction is slated to close by mid-year 2026, pending regulatory approval and environmental conditions.
  • Chemours intends to use the proceeds to reduce its debt obligations.

The big picture

This divestiture represents a significant liquidity event for Chemours, allowing the company to address its debt load and potentially fund other strategic initiatives. The sale to Century Wind Power and Century Iron & Steel suggests a shift in land use priorities in Taiwan, with a move towards renewable energy and industrial development. The $360 million price tag underscores the remaining value in Chemours’ asset base, even as it continues to shed legacy operations.

What we're watching

Environmental Scrutiny
The deal's closure hinges on regulatory approval, including environmental conditions, which could introduce delays or require remediation costs beyond the initially stated proceeds.
Debt Impact
The actual impact on Chemours' debt profile will depend on the final net proceeds after taxes and fees, and how aggressively the company applies the funds to debt repayment.
Strategic Shift
Chemours' decision to exit Taiwan, coupled with the buyer's focus on wind power and steel, signals a potential realignment of Chemours' geographic footprint and product portfolio away from legacy TiO2 assets.
Minto Apartment Real Estate Investment Trust

Minto Apartment REIT Maintains Distribution Amidst Canadian Rental Market Uncertainty

Event summary

  • Minto Apartment REIT declared a January 2026 cash distribution of $0.04458 per unit.
  • The annualized distribution equates to $0.535 per unit.
  • Payment is scheduled for February 17, 2026, to unitholders of record January 31, 2026.
  • The REIT owns multi-residential properties in Toronto, Montreal, Ottawa, Calgary, and Vancouver.

The big picture

Minto Apartment REIT's consistent distribution signals a commitment to returning value to unitholders, but the announcement arrives amidst a complex Canadian rental market facing affordability challenges and potential regulatory shifts. The REIT's portfolio, concentrated in major urban centers, is exposed to these macroeconomic and policy risks. Maintaining this distribution level will require careful management of operating expenses and strategic asset allocation.

What we're watching

Market Conditions
The consistency of this distribution, despite broader economic uncertainties, will be a key indicator of Minto’s ability to navigate potential headwinds in the Canadian rental market, particularly given rising interest rates and affordability concerns.
Portfolio Performance
Future distributions will likely depend on the performance of Minto's portfolio in key urban markets; any signs of weakening occupancy rates or rent growth could pressure distribution levels.
Regulatory Risk
Increased scrutiny of rental market practices and potential regulatory changes in Canada could impact Minto's operational flexibility and profitability, influencing future distribution decisions.
Granite Construction Incorporated

Granite Lands $157M Tucson Infrastructure Project, Bolstered by Grant Funding

Event summary

  • Granite, in a joint venture with Traylor Bros., secured a $157 million contract from the City of Tucson for the 22nd Street Widening and Bridge Replacement Project.
  • The project, commencing in 2025 Q4, involves rebuilding 22nd Street and replacing a bridge with a six-lane structure.
  • Funding sources include the City of Tucson, the Regional Transportation Authority, and a $25 million RAISE Grant.
  • Granite will supply 10,525 tons of asphalt from its Swan Facility.

The big picture

This project underscores the continued demand for infrastructure upgrades in the Southwestern US, fueled by population growth and freight traffic. The inclusion of federal grant funding highlights the increasing reliance on public-private partnerships to finance large-scale construction initiatives. At $157 million, this contract represents a meaningful contribution to Granite’s backlog and reinforces its position as a key player in regional infrastructure development.

What we're watching

Grant Dependency
The project's reliance on a $25 million RAISE Grant introduces a degree of funding risk, as future grant allocations are subject to political and budgetary shifts.
Joint Venture Dynamics
The success of the project hinges on the effective collaboration between Granite and Traylor Bros., and any friction could impact timelines and costs.
Local Sourcing
Granite’s commitment to local asphalt sourcing may offer cost and sustainability advantages, but could also limit flexibility if supply chain disruptions arise.
Hormel Foods Corporation

Hormel Taps Danone Exec to Revitalize Retail Unit

Event summary

  • Domenic Borrelli will join Hormel Foods as Executive Vice President of Retail, effective February 23, 2026.
  • Borrelli previously served as President and General Manager of Danone North America's Beverage Creations business.
  • He brings over 25 years of experience in the food and beverage industry, including roles at Kraft Foods and Maple Leaf Foods.
  • Hormel Foods' Retail business unit represents a significant growth engine for the company, generating approximately $12 billion in annual revenue.

The big picture

Hormel's appointment of Borrelli suggests a recognition that the Retail unit requires a fresh perspective and potentially a significant overhaul. His experience in driving growth at Danone, particularly within beverage categories facing shifting consumer preferences, indicates a focus on revitalizing established brands and adapting to changing market dynamics. The move signals a willingness to bring in external expertise to address challenges within a core business segment.

What we're watching

Execution Risk
Borrelli's success will hinge on his ability to rapidly assess and address any operational or strategic shortcomings within the Retail unit, given his immediate leadership role.
Category Focus
The degree to which Borrelli prioritizes specific categories within the Retail portfolio will signal Hormel's strategic direction and potential shifts in brand investment.
Customer Partnerships
Hormel's future performance will be tied to Borrelli’s ability to strengthen relationships with key retail customers and navigate evolving distribution channels.
Serina Therapeutics, Inc.

Serina Therapeutics Faces NYSE Delisting Threat Amid Equity Deficit

Event summary

  • Serina Therapeutics received a NYSE deficiency notification due to falling below continued listing criteria.
  • The company's stockholders' equity as of September 30, 2025, was reported at $1.6 million.
  • Serina has experienced losses in three of the last four fiscal years.
  • The company must submit a plan to regain compliance by February 8, 2026, with a cure period ending July 9, 2027.

The big picture

This notification highlights the precarious financial position of many clinical-stage biotech companies, particularly those reliant on external funding and facing lengthy development timelines. The NYSE's stricter listing requirements are putting increased pressure on smaller, unprofitable companies to demonstrate a path to profitability. Serina's reliance on its proprietary POZ platform and a single lead candidate, SER-252, amplifies its risk profile and underscores the importance of successful clinical trial outcomes.

What we're watching

Plan Acceptance
The NYSE's acceptance of Serina's remediation plan will be critical; rejection would trigger delisting proceedings and significantly impact investor confidence.
Financial Performance
Whether Serina can achieve profitability within the 18-month cure period will determine its long-term viability and ability to maintain its listing.
Partnership Leverage
The extent to which Serina can leverage its partnership with Pfizer to generate revenue or secure additional funding will be a key indicator of its ability to address its financial challenges.
BriaCell Therapeutics Corp.

BriaCell Raises $30 Million in Public Offering to Fuel Immunotherapy Development

Event summary

  • BriaCell Therapeutics closed a US$30 million public offering of 5,366,726 units on January 15, 2026.
  • Each unit consists of a common share (or pre-funded warrant) and a warrant, priced at US$5.59 per unit.
  • The warrants, trading under the symbol BCTXL, are immediately exercisable at US$6.93 per share and expire in five years.
  • Proceeds will be used for working capital, general corporate purposes, and advancing the company’s business objectives.
  • The offering leveraged a TSX exemption related to interlisted issuers on recognized exchanges like Nasdaq.

The big picture

BriaCell's successful capital raise underscores the ongoing investor interest in immunotherapy, a sector attracting significant funding despite inherent risks. The reliance on a TSX exemption suggests a potential challenge in accessing capital through standard exchange routes, which may reflect investor sentiment or company-specific factors. This offering provides a crucial lifeline for a clinical-stage biotech, but its long-term success hinges on translating this capital into tangible clinical advancements.

What we're watching

Financial Runway
The company's ability to effectively deploy the US$30 million will be critical; investors should monitor burn rate and progress against stated objectives to assess the longevity of this funding.
Warrant Dynamics
The immediate exercisability of the warrants introduces potential dilution risk, and the exercise price will influence future capital needs and shareholder dilution.
Clinical Progress
The press release lacks specifics on how the capital will accelerate clinical development; progress in BriaCell’s immunotherapy programs will be a key determinant of future valuation.
Gibbs Mura, A Law Group

$556 Million Settlement Exposes Medicare Advantage Risk Adjustment Vulnerabilities

Event summary

  • Kaiser Permanente has agreed to a $556 million settlement to resolve allegations of Medicare Advantage risk-adjustment fraud.
  • The settlement, believed to be the largest ever under the False Claims Act for Medicare Part C, involved whistleblower Ronda Osinek, who initially filed the complaint in 2021.
  • The lawsuit alleged Kaiser systematically pressured physicians to alter medical records to inflate Medicare claims.
  • The Department of Justice joined the case in 2021, significantly escalating the legal action.

The big picture

This settlement underscores the growing risks associated with Medicare Advantage billing practices, particularly as the program continues to expand and represents a significant portion of Medicare spending. The substantial size of the settlement signals a heightened commitment from the Department of Justice to aggressively pursue healthcare fraud, potentially impacting the entire industry. The case also highlights the increasing importance of robust internal compliance programs and whistleblower protections within healthcare organizations.

What we're watching

Regulatory Headwinds
Increased scrutiny of Medicare Advantage risk-adjustment practices is likely, potentially leading to more audits and stricter compliance requirements for other insurers.
Governance Dynamics
The case highlights the potential for significant financial and reputational damage stemming from internal compliance failures and the courage of individual employees to report wrongdoing.
Execution Risk
Kaiser's ability to maintain profitability and investor confidence will be tested as it absorbs the financial impact of the settlement and addresses underlying systemic issues.
Lattice Semiconductor

Lattice FPGA Family Gains Recognition for Post-Quantum Security

Event summary

  • Lattice Semiconductor's MachXO5-NX TDQ FPGA family won the 2026 BIG Innovation Award.
  • The FPGA family is the industry’s first to offer CNSA 2.0-compliant post-quantum cryptography (PQC), crypto-agility, and a hardware Root of Trust.
  • The MachXO5-NX TDQ family is built on Lattice's Nexus platform.
  • The award recognizes Lattice’s focus on secure control FPGAs for applications including Computing, Communications, Industrial, and Automotive.

The big picture

The award underscores the increasing importance of post-quantum cryptography in securing critical infrastructure. As quantum computing capabilities advance, the risk of attacks on existing cryptographic systems grows, driving demand for solutions like Lattice’s PQC-ready FPGAs. This positions Lattice to benefit from a growing market, but also necessitates continuous innovation to maintain its competitive edge.

What we're watching

Adoption Rate
The speed at which customers adopt this PQC-ready FPGA will be a key indicator of Lattice's ability to capitalize on growing cybersecurity concerns in critical infrastructure.
Competitive Response
Other FPGA vendors will likely accelerate their own PQC development efforts, potentially leading to price pressure or feature parity in the coming years.
Standard Evolution
The ongoing evolution of post-quantum cryptography standards and the potential for CNSA 2.0 revisions will necessitate ongoing investment and design flexibility from Lattice.
The Rockefeller Foundation

Rockefeller Foundation Bets $220M on Food System Transformation

Event summary

  • The Rockefeller Foundation premiered a documentary, 'FOOD 2050,' narrated by Viola Davis, focusing on solutions to feed a global population of 10 billion by 2050.
  • The Foundation has committed over $220 million to nutrition initiatives, including $100 million for regenerative school meals and $100 million for 'Food is Medicine' programs.
  • The documentary originated from the Foundation's Food System Vision Prize, aimed at fostering community-led blueprints for food systems.
  • Media RED, an award-winning studio, partnered with The Rockefeller Foundation and Food Tank to produce the documentary.
  • The film will next be screened at the Sundance Film Festival on January 24, 2026, as part of Food Tank's annual programming.

The big picture

The Rockefeller Foundation's $220 million commitment underscores the growing recognition of systemic food system vulnerabilities exacerbated by climate change and population growth. This initiative, leveraging documentary filmmaking and strategic partnerships, represents a shift towards community-led solutions and a broader 'Food is Medicine' approach, reflecting a move away from traditional philanthropic models towards more catalytic and impact-driven investments. The Foundation's scale—$30 billion invested over 113 years—positions it as a key influencer in shaping the future of global food security.

What we're watching

Grassroots Impact
The success of the 'FOOD 2050' campaign hinges on its ability to translate high-level commitments into tangible grassroots momentum, which will be tested by the planned impact campaign in 2026.
Policy Alignment
How effectively the Foundation's 'Big Bets'—particularly the school meals and 'Food is Medicine' initiatives—align with evolving government policies and regulatory frameworks will determine their long-term sustainability.
Visionary Adoption
The rate at which the solutions highlighted in the documentary are adopted by commercial agricultural entities and food producers will dictate the overall impact on global food systems.
Canadian Radio-television and Telecommunications Commission (CRTC)

CRTC Mandates Data Transparency to Spur Canadian Broadband Investment

Event summary

  • The CRTC approved a decision to release more detailed data on internet and cellphone service providers, technologies, and speeds available to Canadians.
  • The CRTC is launching a public consultation to standardize the collection and reporting of cellphone coverage data, concluding March 16, 2026.
  • The data released will be used to update ISED's National Broadband Map.
  • The CRTC’s actions follow a series of initiatives aimed at empowering Canadian consumers.

The big picture

The CRTC's actions represent a shift towards greater transparency and accountability within Canada’s telecom sector. This move, coupled with ISED’s National Broadband Map, aims to address persistent coverage gaps and improve consumer choice, potentially reshaping the competitive dynamics of a market vital to Canada's digital economy. The standardization of mobile coverage data reporting could also influence future regulatory decisions and investment strategies.

What we're watching

Competitive Landscape
Increased data transparency will likely intensify competition among Canadian telecom providers, potentially leading to price adjustments and service upgrades to attract customers.
Investment Flows
The CRTC’s decision to make data available may incentivize further private investment in broadband infrastructure, particularly in underserved areas, as investors gain a clearer view of market opportunities.
Regulatory Scrutiny
The public consultation on mobile coverage reporting standards will likely reveal tensions between service providers’ desire for streamlined reporting and the CRTC’s need for accurate and granular data.
Canadian Labour Congress / Congrès du travail du Canada

Canadian Unions Signal Hard Line in CUSMA Review Amid U.S. Tariff Threats

Event summary

  • Canadian unions, led by CLC President Bea Bruske, held a roundtable with Minister Dominic LeBlanc to discuss the upcoming 2026 CUSMA review.
  • Unions warned the Canadian government against prioritizing a trade agreement over protecting Canadian jobs and industries.
  • The CLC is advocating for a 'workers-first' trade policy focused on preserving jobs, strengthening domestic industry, and maintaining regulatory space.
  • Renewed U.S. tariff threats on sectors like auto and softwood lumber are cited as contributing to production and job losses in Canada.

The big picture

The Canadian Labour Congress's stance highlights a growing divergence between Canada's desire for an independent industrial policy and the increasingly protectionist trade practices of the United States. This tension poses a significant challenge for the Canadian government as it seeks to modernize CUSMA while safeguarding domestic industries and jobs. The outcome of these negotiations will have far-reaching implications for North American trade and the balance of economic power.

What we're watching

Negotiating Leverage
Canada's ability to resist U.S. demands during the CUSMA review will depend on its willingness to risk a breakdown in negotiations, potentially impacting supply chains and economic growth.
Tariff Resolution
The removal of U.S. sectoral tariffs on Canadian industries will be a key indicator of the success of the government's efforts to defend Canadian economic interests.
Labor Chapter Enforcement
The effectiveness of any strengthened labor chapter, particularly the Rapid Response Mechanism, will determine whether CUSMA can meaningfully protect workers' rights across North America.
Breakthrough T1D

Breakthrough T1D Funds Virtual Care Expansion Amid Healthcare Coverage Shifts

Event summary

  • Breakthrough T1D (formerly JDRF) awarded Blue Circle Health a $1.5 million, three-year grant.
  • The grant aims to improve insurance navigation and continuity of care for adults with Type 1 Diabetes (T1D).
  • Blue Circle Health provides free, virtual care and support services for adults with T1D.
  • The funding responds to increasing challenges related to Medicaid and Affordable Care Act coverage changes.
  • Adults account for nearly 50% of all T1D diagnoses globally.

The big picture

The grant highlights the growing intersection of healthcare access, insurance coverage volatility, and the needs of individuals with chronic conditions like Type 1 Diabetes. Changes to government healthcare programs are creating significant barriers to care, particularly for vulnerable populations, and organizations like Breakthrough T1D are increasingly directing resources to address these gaps. The virtual care model employed by Blue Circle Health represents a potential solution for expanding access, but its long-term viability depends on sustained funding and demonstrated effectiveness.

What we're watching

Policy Impact
Future Medicaid and Affordable Care Act policy changes will likely continue to drive demand for services like those offered by Blue Circle Health, potentially impacting grant funding needs and program scalability.
Care Model
The success of Blue Circle Health’s community-centered, virtual care model will be a key indicator of whether this approach can effectively address the challenges faced by underserved T1D patients.
Funding Sustainability
Breakthrough T1D’s reliance on grants to support critical care services raises questions about the long-term financial sustainability of these programs and potential diversification of funding sources.
Life Time Group Holdings, Inc.

Life Time, Evereve Collaborate on Apparel Line to Expand Wellness Ecosystem

Event summary

  • Life Time and Evereve, a women's fashion retailer, are launching a 15-piece capsule collection on January 22, 2026.
  • The collection, designed by Evereve’s team, is priced between $36 and $88 and will be available in 113 Evereve locations, 29 Life Time locations, and online.
  • The collection aims to blend athletic-inspired apparel with everyday style, targeting women who value both fitness and fashion.
  • Evereve Co-Founder and Co-CEO Megan Tamte highlighted the partnership's alignment with both brands' missions of empowering women.

The big picture

This collaboration represents a strategic move by Life Time to diversify its revenue streams beyond membership fees and deepen its engagement with a broader female demographic. Evereve, with its established online presence and curated fashion approach, provides Life Time with a valuable distribution channel and brand association. The partnership signals a growing trend of wellness brands expanding into lifestyle apparel and accessories to capture a larger share of consumer spending.

What we're watching

Consumer Adoption
The success of the collection hinges on consumer reception and whether the 'sporty, styled up' aesthetic resonates with Life Time members and Evereve shoppers, potentially expanding both brands' reach.
Channel Conflict
Life Time's decision to sell the collection through Evereve stores and online raises questions about potential channel conflict and its impact on Life Time's existing retail strategy.
Brand Synergy
The long-term impact of this collaboration will depend on whether it fosters genuine brand synergy and drives incremental revenue for both Life Time and Evereve, or remains a limited-time promotional effort.
Veraxa Ltd.

Score11 Token Launches on Coinstore, Betting on Web3 Fantasy Sports

Event summary

  • Score11, a Web3 fantasy sports platform, is launching its native token, SCR, via an Initial Exchange Offering (IEO) on Coinstore.
  • The SCR token will trade as SCR/USDT, with trading beginning January 21, 2026, following a private sale starting January 16, 2026.
  • The total supply of SCR is 100,000,000 tokens, built on the Binance Smart Chain (BSC).
  • Score11’s platform incorporates features like staking rewards, NFT collectibles, and a decentralized prediction market using stablecoins (USDT, USDC).

The big picture

Score11’s IEO represents a growing trend of integrating blockchain technology and tokenization into traditional industries like sports and gaming. The platform’s focus on skill-based competition and verifiable outcomes aims to address criticisms of traditional fantasy sports, while the decentralized prediction market introduces a novel element of financial participation. However, the nascent Web3 sports market faces challenges related to user adoption, regulatory scrutiny, and the sustainability of token-driven economies.

What we're watching

Adoption Rate
The success of SCR will hinge on Score11’s ability to attract and retain users within the competitive fantasy sports and Web3 landscape, and the circulating supply will be a key indicator of this.
Regulatory Risk
The decentralized prediction market component introduces regulatory uncertainty, particularly regarding gambling laws and securities classifications in various jurisdictions.
Ecosystem Growth
The platform’s expansion into football and esports, as well as the development of a DAO for governance, will be crucial for long-term utility and value accrual for SCR holders.
Command Alkon Incorporated

Command Alkon Integrates Giatec's AI-Powered Concrete Platform

Event summary

  • Command Alkon has added Giatec Scientific to its Connected Partner Program.
  • The integration allows Command Alkon Dispatch users to leverage Giatec’s SmartMix platform for concrete quality control.
  • SmartMix utilizes AI to optimize concrete mix designs, targeting cost, CO2, and workability improvements.
  • Giatec’s CTO and Co-founder, Aali Alizadeh, highlighted the partnership's role in driving profitability and efficiency.
  • Command Alkon’s CPO, Ranjeev Teelock, stated the integration will redefine concrete production quality control.

The big picture

The construction materials industry is increasingly adopting digital solutions to improve efficiency and sustainability. Command Alkon’s Connected Partner Program represents a strategic move to expand its platform’s functionality and lock in customers, while Giatec gains broader market access for its AI-powered concrete technology. This partnership underscores the growing importance of data-driven decision-making in a sector facing rising material costs and environmental pressures.

What we're watching

Adoption Rate
The success of this partnership hinges on the adoption rate of SmartMix within Command Alkon’s existing customer base; slow uptake could limit the strategic impact.
Competitive Response
Other concrete technology providers will likely accelerate their own integration efforts or partnerships to counter Command Alkon’s enhanced offering.
Data Security
As Giatec’s data flows through Command Alkon’s platform, the robustness of their combined data security protocols will be critical to maintaining customer trust and avoiding regulatory scrutiny.
Ipsos Group S.A.

Ipsos Appoints Stoclet as Chair Amid Founder's Health Departure

Event summary

  • Didier Truchot, Chairman of Ipsos, is resigning due to ongoing health issues related to digestive tract cancer, effective February 28, 2026.
  • Laurence Stoclet, former CFO and Deputy CEO of Ipsos, is being appointed as the new Chair of the Board, effective March 1, 2026.
  • Anne-Marie Couderc has been appointed as Lead Independent Director to strengthen governance.
  • Truchot will remain on the Board and as a significant shareholder, retaining the title of Chairman Emeritus.

The big picture

The sudden departure of Ipsos' Chairman highlights the inherent risks associated with key-person dependencies in leadership. Laurence Stoclet’s appointment brings a seasoned executive with deep operational and financial expertise back to a central role, potentially signaling a shift towards greater efficiency and strategic focus. Given Ipsos’ global presence and significant market share, this leadership transition will be closely watched by investors and competitors alike.

What we're watching

Governance Dynamics
The transition of leadership presents an opportunity to assess the Board's effectiveness and its alignment with Ipsos' strategic priorities, particularly given Stoclet's prior executive roles.
AI Integration
Truchot's emphasis on AI integration suggests Ipsos will accelerate investment and innovation in this area, requiring close monitoring of its impact on revenue and margins.
Execution Risk
Stoclet’s prior involvement in over 100 acquisitions suggests a potential for further M&A activity, which will need to be carefully managed to avoid integration challenges and value destruction.
INFORMA MARKETS LIMITED

WWETT Show Highlights $630 Billion Clean Water Infrastructure Need

Event summary

  • The Water & Wastewater Equipment, Treatment and Transport (WWETT) Show will be held February 16-19, 2026, in Indianapolis.
  • The EPA estimates $630.1 billion is needed for U.S. clean water infrastructure improvements over the next two decades.
  • The WWETT Show features over 500 exhibitors across 100+ product categories.
  • The inaugural Women of Wastewater Awards will be presented at the event, alongside a dedicated Women in Wastewater track.

The big picture

The WWETT Show underscores the critical need for infrastructure upgrades in the U.S. water sector, driven by regulatory mandates and aging infrastructure. The event's focus on innovation and workforce development signals a broader industry transformation, as companies seek to meet escalating demands with new technologies and address talent shortages. The $630 billion funding gap represents a substantial opportunity for equipment providers and service companies, but also a significant hurdle requiring creative financing and efficient execution.

What we're watching

Funding Dynamics
The scale of the EPA’s $630.1 billion funding need suggests significant pressure on both public and private sector investment, potentially driving M&A activity among equipment providers.
Technology Adoption
The presence of numerous first-time exhibitors, particularly those focused on digital and smart technologies, indicates a rapid acceleration in the adoption of new solutions within the wastewater sector.
Workforce Evolution
The focus on women in wastewater and the inclusion of mental health topics suggests a growing awareness of workforce challenges and a potential shift in industry demographics and practices.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Kelun-Biotech Highlights ADC Pipeline, Global Ambitions at JPM Healthcare Conference

Event summary

  • Kelun-Biotech showcased its ADC and novel drug conjugate (DC) pipeline at the JPM Healthcare Conference on January 15, 2026.
  • The company has two ADC products on the market (sacituzumab tirumotecan and trastuzumab botidotin) and nine ADC/DC drugs in clinical stages.
  • Results from the OptiTROP-Lung04 study of sac-TMT were published in The New England Journal of Medicine.
  • Kelun-Biotech has five commercialized products in China, three of which are on the National Reimbursement Drug List (NRDL).

The big picture

Kelun-Biotech's emergence as a leader in China's innovative drug field, particularly in ADCs, reflects the broader trend of increased investment and innovation within the Chinese biopharmaceutical sector. The company's focus on high-incidence cancers aligns with China's growing healthcare needs and government support for domestic drug development. The partnership with MSD signals an ambition to compete on a global scale, but also introduces dependencies and potential IP-related risks.

What we're watching

Globalization
The success of Kelun-Biotech's collaborations with MSD and other partners will be critical for its international expansion and ability to recoup R&D investments.
Clinical Execution
The pace of clinical trial enrollment and data readouts for the nine pivotal studies in China will dictate the timeline for potential market expansion and revenue growth.
Platform Risk
While the OptiDC™ platform is a key differentiator, its ability to consistently generate novel, effective ADC/DC candidates will determine Kelun-Biotech’s long-term competitive advantage.
Viz.ai, Inc.

Viz.ai Integrates Clinical Data with Salesforce Agentforce to Target Pharma Engagement

Event summary

  • Viz.ai and Salesforce have launched a new real-time clinical intelligence service for Salesforce’s Agentforce Life Sciences.
  • The integration connects Viz.ai’s data from nearly 2,000 hospitals (covering 230M lives) to Salesforce’s Agentforce platform.
  • The service aims to power agentic workflows for life sciences companies, enabling targeted education and support for clinicians and patients.
  • Over 110 life science companies have already adopted Agentforce Life Sciences.
  • Viz.ai’s Data 360 connector will be available through the Salesforce AppExchange.

The big picture

The collaboration reflects a growing trend of pharmaceutical companies leveraging real-time data and AI-powered agents to personalize patient engagement and optimize commercial strategies. This move signals a shift away from traditional, volume-based sales models towards value-based care and data-driven decision-making. The integration of Viz.ai’s clinical intelligence with Salesforce’s Agentforce platform represents a significant step towards creating a more connected and responsive healthcare ecosystem.

What we're watching

Adoption Rate
The success of this partnership hinges on the ability of life sciences companies to integrate the new service into existing workflows and demonstrate tangible ROI, which will dictate the pace of broader adoption.
Data Privacy
Given the sensitivity of patient data involved, regulatory scrutiny and compliance challenges will be a key factor in the long-term viability of the offering.
Competitive Response
Other healthcare AI and CRM providers will likely accelerate their own integration efforts, potentially eroding Viz.ai and Salesforce’s first-mover advantage.